Our experience in this area is specific to complex immunocompromised patient populations susceptible to opportunistic infections.
Learn More
CTI Announces Acquisition of Middle East/Northern African based Clinart
“We are excited to have Clinart join CTI to create a stronger and more robust global full-service clinical research organization,” remarked Patrick J. Earley, CTI’s Chief International Business Officer. “This acquisition has been in the works for quite some time, and despite the global crises we’re currently experiencing, we felt passionately about moving this deal forward for the future success of our organization. In fact, this merger will allow both companies to continue and expand the global reach of their important work in COVID-19 research.”
CTI Named #1 CRO in the World for Quality at 2020 CRO Leadership Awards
"The CTI team has always been dedicated to providing the highest quality service to our sponsors," remarks Timothy Schroeder, Founder and CEO of CTI. "Congratulations to the other 30 or so CROs, who were chosen out of thousands for their high standards. We are extremely proud to be recognized as the CRO with the highest quality in the world. We pride ourselves on all of these award qualities - being reliable, providing expertise, being easy to work with, etc., and it is an honor to consistently hear from an external, unbiased source that we are successful in demonstrating those characteristics to our partners."
Medidata Partners with CTI for Remote Source Review of Clinical Trials in Response to COVID-19
“Medidata is committed to developing and deploying the technology necessary to maintain the momentum of discovery,” said Glen de Vries, co-founder and co-CEO, Medidata. “We’re pleased to be partnering with CTI on these important, promising trials for patients with rare and infectious diseases, and cancer. It’s more important than ever that we think and plan our way around the obstacles COVID-19 has put in the path of medical progress.”
CTI Partners with St. Elizabeth Healthcare and Pulmotect to Open First Hospital Site for Phase-2 Clinical Trial Targeting COVID-19
“The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety,” said Tim Schroeder, Founder and CEO of CTI. "We are proud to have the opportunity to collaborate on such a response with the St. Elizabeth team and to work together to develop an effective treatment solution for those hardest hit by COVID-19."
CTI Partners with Pulmotect on Two Phase-2 Trials Targeting COVID-19
“We are thrilled to be working with Pulmotect on these programs,” remarked Timothy Schroeder, CEO of CTI. “The research into PUL-042 for the treatment of patients with COVID-19 is a prime example of how the scientific community can leverage existing science and approach it in an innovative way to develop treatments for novel diseases. We are privileged to be able to help develop these innovative strategies and bring treatments to those in need.”
CTI Partners with Humanigen for Planned Phase III Study for Lenzilumab for Coronavirus Treatment
“The COVID-19 pandemic demands an unprecedented response from the pharmaceutical and biotechnology communities, requiring innovation, collaboration, and prioritization of speed without the cost of safety,” remarked Tim Schroeder, founder and CEO of CTI. "We are proud to have the opportunity to collaborate on such a response with the Humanigen team and to work together to develop an effective treatment solution for those hardest hit by COVID-19.”
How CTI Can Help Fight the Impact of COVID-19
CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. Whether that means helping adjust programs impacted by the pandemic, developing new programs to help our sponsors create effective treatments for infected patients, or simply providing support to our communities and team members, we are here to help.
Infectious Diseases
COVID-19
CTI is dedicated to helping our partners, team members, and communities work through the COVID-19 pandemic. We are currently working on more than 15 COVID-19 programs, including global vaccine studies and treatment programs.
Learn MoreLate Phase & Expanded Access Programs
CTI has the global infrastructure, site relationships, and health outcomes expertise to execute Phase IV, Registry, and Expanded Access Programs effectively.
Learn MoreVolunteer for a COVID-19 Study
Join our database of participants for future COVID-19 clinical research trials
Learn MoreJoin our team
CTI is always looking for talented individuals to work on life-changing therapies around the world
Learn MoreLatest News
CTI Clinical Trial & Consulting Global Headquarters
100 E. RiverCenter Blvd.
Covington, KY 41011
Covington, KY 41011
Main Phone: +1.513.598.9290
Main Fax: +1.859.261.3757
Main Fax: +1.859.261.3757
Where Life-changing Therapies Turn First®
CTI is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization.
© 2020 CTI Clinical Trial and Consulting Services
All rights reserved.
Follow Us
